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Abbreviations used
APC: Allophycocyanin
BCR: B-cell receptor
B-LCL: EBV-immortalized B-lymphoblastic cell line
CADD: Combined annotation-dependent depletion
CDR: Complementarity-determining region
FITC: Fluorescein isothiocyanate
fMLP: N-formyl-methionyl-leucyl-phenylalanine
ICAM-1: Intercellular adhesion molecule 1
IRM: Interference reflection microscopy
PE: Phycoerythrin
PID: Primary immunodeficiency
SHM: Somatic hypermutation
SLB: Supported lipid bilayer
TCR: T-cell receptor
Tfh: Follicular helper T
TIRF: Total internal reflection fluorescence
TLR: Toll-like receptor
WAS: Wiskott-Aldrich syndrome
WASP: Wiskott-Aldrich syndrome protein
WDR1: WD repeat–containing protein 1
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2 PFAJFER ET ALBackground: The actin-interacting protein WD repeat–
containing protein 1 (WDR1) promotes cofilin-dependent actin
filament turnover. Biallelic WDR1 mutations have been identified
recently in an immunodeficiency/autoinflammatory syndrome
with aberrant morphology and function of myeloid cells.
Objective: Given the pleiotropic expression of WDR1, here we
investigated to what extent it might control the lymphoid arm of
the immune system in human subjects.
Methods: Histologic and detailed immunologic analyses were
performed to elucidate the role of WDR1 in the development
and function of B and T lymphocytes.
Results: Here we identified novel homozygous and compound
heterozygous WDR1 missense mutations in 6 patients belonging
to 3 kindreds who presented with respiratory tract infections,
skin ulceration, and stomatitis. In addition to defective adhesion
and motility of neutrophils and monocytes, WDR1 deficiency
was associated with aberrant T-cell activation and B-cell
development. T lymphocytes appeared to develop normally in
the patients, except for the follicular helper T-cell subset.
However, peripheral T cells from the patients accumulated
atypical actin structures at the immunologic synapse and
displayed reduced calcium flux and mildly impaired
proliferation on T-cell receptor stimulation. WDR1 deficiency
was associated with even more severe abnormalities of the B-cell
compartment, including peripheral B-cell lymphopenia, paucity
of B-cell progenitors in the bone marrow, lack of switched
memory B cells, reduced clonal diversity, abnormal B-cell
spreading, and increased apoptosis on B-cell receptor/Toll-like
receptor stimulation.
Conclusion: Our study identifies a novel role forWDR1 in adaptive
immunity, highlighting WDR1 as a central regulator of actin
turnover during formation of the B-cell and T-cell immunologic
synapses. (J Allergy Clin Immunol 2018;nnn:nnn-nnn.)
Key words: WD repeat–containing protein 1, actin cytoskeleton,
immunodeficiency, lymphocytes, immunologic synapse
Actin cytoskeletal dynamics drive a wide array of cellular
processes, such as morphogenesis, polarity, and motility.1 Actin
regulators work in concert to tune the assembly and turnover of
actin filament meshworks at different cellular locations.2 Immune
cell function relies on finely tuned actin cytoskeletal dynamics.
Indeed, both myeloid and lymphoid cells are highly motile and
need to establish dynamic cell-to-cell contacts to execute their
function. The pivotal role of the actin cytoskeleton in driving
immune cell function in human subjects is being revealed by the
characterization of a growing number of inherited defects of the
immune system (primary immunodeficiencies [PIDs]) caused by
deficiency or molecular alteration of actin cytoskeleton–
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-A very recently discovered actin-related PID is caused by
biallelic loss-of-function mutations in the gene encoding
actin-interacting protein 1 (AIP1)/WD repeat–containing
protein 1 (WDR1).4,5 WDR1 is part of a large family of WD
(tryptophan-aspartic acid) repeat domain–containing proteins
that act as molecular scaffolds through a 7-bladed beta-propeller.6
WDR1 is expressed ubiquitously and promotes actin filamen
disassembly through cofilin.7-12 More precisely, actin filamen
disassembly relies on sequential recruitment of coronin, cofilin
and WDR1, which act in concert to sever actin filaments.13-15
WDR1 activity is enhanced further by interaction with the
immunomodulatory protease caspase-11.16
In human subjects defective expression of WDR1 has been
shown recently to affect in particular the innate arm of the immune
system. A first study reported 4 children carrying WDR1 biallelic
mutations resulting in severe immunodeficiency associated with a
prominent defect in neutrophils, which emitted nuclear herniations
and were defective in migrating toward the bacterial chemotactic
peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP).4
A second study reported 2 siblings carrying aWDR1 biallelic mu
tation associated with autoinflammation, immunodeficiency, and
thrombocytopenia.5 Expression of misfolded WDR1 in
monocyte-derived dendritic cells from those patients led to
enlarged actin-rich podosomes and excessive amounts of IL-18
caused by abnormal inflammasome activation. This phenotype is
in linewith a previous study showing that a hypomorphic mutation-
,
-
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matory disease characterized by excessive neutrophil recruitment
to sites of inflammation.17 In thesemice neutrophils show increased
levels of F-actin and cofilin, resulting in mislocalization and
reduced migration.17 Additional studies have linked aberrant
expression of WDR1 in human subjects to gout,18 pancreatitis,19
and primary glioblastoma.20 The extent to which naturally occur-
ringWDR1mutations also affect the adaptive arm of the human im-
mune system has not been investigated.
Here we identified the largest cohort of patients with biallelic
WDR1 mutations to date and set out to systematically dissect the
consequences on different leukocyte subsets, with a particular
focus on lymphocytes.METHODS
Study oversight
The studies, including immunologic diagnostic procedures and genetic
analyses, were performed in accordance with guidelines of good clinical
practice, the current version of the Declaration of Helsinki, written informed
consent from the patients or patient’s legal representatives, and approval from
the relevant institutional review boards.Whole-exome sequencing
For whole-exome sequencing, a TrueSeq Rapid Exome kit, as well as the
Illumina HiSeq3000 system and cBot Cluster Generation instruments
(Illumina, San Diego, Calif), were used, as previously described,21,22 with
minor changes. Briefly, reads were aligned to the human genome version 19
by using the Burrows-Wheeler Aligner. Variant Effect Predictor was used
for annotating single nucleotide variants and insertion/deletion lists. The
obtained list was then filtered, excluding variants with a minor allele fre-
quency of greater than 0.01 in the 1000 Genomes, Exome Aggregation Con-
sortium, or dbSNP build 149 databases. After further filtering steps for
nonsense, missense, and splice-site variants, an internal database was used
to filter for recurrent variants.Moreover, variants are prioritized by using tools,
such as SIFT, Polyphen-2, and the combined annotation-dependent depletion
(CADD) score,23 that predict the deleteriousness of a present variant.
Homozygosity mapping
Homozygous sections are mapped with H3M2 (Homozygosity
Heterogeneous Hidden Markov Model) software,24 allowing screening for
variants segregating with patient phenotype.Sanger sequencing
Sanger sequencing was used to validate the WDR1 variants c.C435G
(H145Q) in exon 5 and c.A1715T (D572V) in exon 15 obtained from
whole-exome sequencing in the affected family members. Variants in family
3 (D572V in exon 15 and G501S in exon 13) were obtained from direct Sanger
sequencing. This was done by designing specific primers for all the
variants found: for H145Q in introns 4 and 5 and exon 5/introns 5 and 6, 59-
GTTCTTGGGTCCTTTGGAC -39 (F1) and 59- CACTTACGCCAATTGT-
GAACT -39 (R1); for D572V in introns 14 and 15 and the 39 untranslated
region, 59- CTAGTCCCTGATTCGGTCCA -39 (F2) and 59- CAGGAGTGT
CACGTGGAGAA -39 (R2); and for c.G1501A (G501S) in introns 12 and
13 and introns 13 and 14, 59- AGGATGGGTGTGGTGTGTG -39 (F3) and
59- ACAGATAACCTCCCACTGCC -39 (R2).WDR1 expression
Patient and healthy donor PBMCs were lysed in 100 mL RIPA buffer
(150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
and 50 mmol/L TRIS [pH 8.0]), run on a 10% acrylamide gel at 120 V, and
blotted overnight at 120 mA at 48C on a polyinylidene difluoride membrane.Membranes were incubated with anti-human WDR1 (Novus Biologicals,
Littleton, Colo) polyclonal antibody at a dilution of 1:600 in Tris-buffered
saline with 0.5% Tween and 5% milk overnight at 48C and a secondary
anti-rabbit antibody at room temperature for 2 hours. As a control,
glyceraldehyde-3-phosphate dehydrogenase (clone 86C5; Santa Cruz
Biotechnology, Dallas, Tex) at a dilution of 1:1000 in combination with a
secondary horseradish peroxidase–conjugated goat anti-mouse antibody
diluted 1:30,000 was used. Blots were developed with ECL (GE Healthcare,
Fairfield, Conn).Immunophenotyping
Healthy donor and patient PBMCs were obtained by using Ficoll density
centrifugation and stained for 30 minutes at 48C with the following mouse
anti-human antibodies: CXCR5–allophycocyanin (APC; 51505) from R&D
Systems (Minneapolis, Minn); CCR7–phycoerythrin (PE)-CF594 (150503),
CD27 V450 (M-T271), CD27 Brilliant Violet (M-T271), CD38–PE-Cy7
(HIT2), CD21-PE (B-ly4), CD3–APC-H7 (SK7), CD5–Alexa Fluor 700
(UCHT), CD4-APC (RPA-T4), CD4–Brilliant Violet 605 (RPA-T4),
CD45RA–Alexa Fluor 700 (HI100), CD8-V500 (RPA-T8), CD8–fluorescein
isothiocyanate (FITC; HIT8a), IgM-APC (G20-1273), IgD-FITC (IA6-2),
and CD95–PE-Cy7 (DX2) from BD PharMingen (San Jose, Calif);
CD19–peridinin-chlorophyll-protein complex-Cy5.5 (HIB19), CD10-APC
(CB-CALLA), and CD31-APC (WM59) from eBioscience (San Diego,
Calif); CD14–PE-Cy7 (RMO52), CD56-PE (N901), CD4-PE (13B8.2),
T-cell receptor (TCR)–Vb11-FITC (C21), and TCR-Va24–PC-7 (C15)
from Beckman Coulter; and CD8-V450 (RPA-T8) from BD Horizon (BD
Biosciences, Franklin Lakes, NJ). Stained cells were analyzed on a BD LSR
Fortessa cytometer. Data were processed with FlowJo X software (TreeStar,
Ashland, Ore) and sketched with Prism 6.0 software (GraphPad Software,
La Jolla, Calif).Confocal microscopy
On isolation from peripheral blood samples, neutrophils, monocytes, and
T cells were transferred onto glass slides precoated with 2 mg/mL fibronectin
(all cells) or 10 mg/mL anti-CD3mAbs (T cells). Neutrophils were stimulated
in parallel with 10 nmol/L fMLP, whereas monocytes were treated with
50 ng/mL LPS. After 1 hour of incubation at 378C, cells were fixed with PFA
3% and stained with Phalloidin–Alexa Fluor 488 (1:40 dilution) for 1 hour in
permeabilization buffer (eBioscience) at room temperature in the dark. Slides
were imaged with a Zeiss LSM700 confocal microscope (Zeiss, Oberkochen,
Germany). The acquired images were analyzed with the ImageJ software
(National Institutes of Health, Bethesda, Md).Histologic and immunohistologic bone marrow
examination
Histologic staining of paraffin-embedded tissue sections of 2 decalcified
bone marrow biopsy specimens was performed, as previously described.25
Immunohistologic staining was done with a panel of antibodies against
CD10, CD22, CD3, and CD5 from Novocastra (Newcastle upon Tyne, United
Kingdom); CD19, CD20, CD117, CD79a, paired box 5 (PAX-5), and terminal
deoxynucleotidyl transferase (TdT) from DAKO (Glostrup, Denmark); and
CD71, CD34, CD61, CD14, and tryptase from Cell Marque (Rocklin, Calif)
on an automated Leica BOND III immunohistological stainer (Leica,Wetzlar,
Germany). Total bone marrow cellularity and representation of individual
lineages were estimated by comparing the individual cellular compartments
with age-matched control tissue.
Neutrophil migration
Ninety-six-well transwell plates containing a 5-mm pore size membrane
(Corning, Corning, NY) were used to assess cell migration toward
chemoattractants. Freshly isolated neutrophils (5 3 104 cells in 50 mL)
were loaded on the top of the transwell filter, and 150 mL of fMLP was added
at the indicated concentrations to the lower chamber. After 30 minutes
FIG 1. Identification of novelWDR1mutations in 3 kindreds.A,Aphthous stomatitis in patient P1.B,Skin infec-
tion on the calf of patient P3. C, Skin ulceration on the calf of patient P5. D, Pedigree of family A. E, Pedigree of
family B. F, Pedigree of family C.G, Sanger validation ofWDR1mutation in patient P1 (c.C435G, p.His145Gln).
H, Sanger validation of WDR1 mutation in patient P2 (c.A1715T, p.Asp572Val). I, Sanger validation of the
compound heterozygous variants in patient P5 (c.A1715T, p.Asp572Val and c.G1501A, p.Gly501Ser) and homo-
zygous variant in patient P6 (c.A1715T, p.Asp572Val). J, Three-dimensional structure ofWDR1with localization
of the identified variants. K, Representative Western blot analysis of WDR1 expression in lysates from PBMCs
isolated from 2 healthy donors and the 6 patients. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
shown as the loading control. The data correspond to 1 experiment of 2 performed. HD, Healthy donor.
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TABLE I. Clinical characteristics of the patients
Family A B C
Patient 1 2 3 4 5 6
Sex Male Female Male Male Female Female
Ethnic origin Turkish Turkish Turkish Turkish Syrian Syrian
Current age (y) 11 12 21 24 26 7
Age at onset (y) 2.5 9 11 14 NA NA
Consanguinity Yes Yes Yes Yes No Yes
Clinical presentation
General Recurrent fever
(4- to 6-mo
intervals)
No dysmorphy
obvious facial
Diarrhea and
vomiting
Weight and height:
27 kg (0 SDS,
50th-75th
percentile)
and 128 cm (0.2
SDS, 50th-75th
percentile) at time
of admission
(8 y)
No recurrent fever
Facial dysmorphy
(frontal bossing,
minimal
hypertelorism,
wide nasal
nostrils)
No gastrointestinal
manifestations
Weight and height:
16.7 kg (23.9
SDS, <3rd
percentile)
and 112 cm
(23.6 SDS,
<3rd percentile)
No recurrent fever
Facial dysmorphy
(frontal bossing,
minimal
hypertelorism,
wide nasal nostrils)
Diarrhea
Weight and height:
43 kg [23.8 SDS,
<3rd percentile] and
162 cm (22 SDS,
<3rd percentile)
No recurrent fever
Facial dysmorphy
(frontal bossing,
minimal
hypertelorism,
wide nasal
nostrils)
Diarrhea
Weight and height:
50 kg (22.5 SDS,
<3rd percentile)
and 168 cm
(21.2 SDS,
10th-25th
percentile)
No recurrent
fever
No obvious
facial dysmorphy
No gastrointestinal
manifestations
Weight and
height: 75 kg
(11.2 SDS,
90th percentile)
and 160 cm
(20.5 SDS,
25th-50th
percentile)
Recurrent fever
(1-to 2-mo
intervals)
No obvious
facial
dysmorphy
No gastrointestinal
manifestations
Weight and
height: 20 kg
(25th percentile)
and 116 cm
(10th-25th
percentile)
Neurological Mental impairment
(WISC-R test;
Verbal IQ: 72,
Performance
IQ: 84
Total IQ: 75)
Learning difficulty
in school,
no formal
test performed
Learning difficulty
in school,
no formal
test performed
Learning difficulty
in school, no
formal test
performed
Learning difficulty
in school, no
formal test
performed
Learning difficulty
in school, no
formal test
performed
Infections Pneumonia
Aphthous stomatitis
Oral candidiasis
Pneumonia
Bronchiectasia
Aphthous
stomatitis
Otitis
Encephalitis
(suspected from
viral infection;
responsible agent
not isolated)
Lymphadenopathy
Abscesses
Varicella infection
Burkholderia
gladioli isolated
from skin abscess
Pneumonia
Bronchiectasia
Nodulocystic acne
Skin ulcers
Pyoderma
gangrenosum
HBV carrier
Staphylococcus
aureus infection
Bronchitis
Bronchiectasia
Nodulocystic
acne
Abscesses
Skin ulcers
Lymphadenopathy
Pyoderma
gangrenosum
HBV carrier
Staphylococcus
aureus infection
Aphthous
stomatitis
Otitis media
Sinusitis
Pharyngitis
Abscesses
Pneumonia
Aphthous
stomatitis
Vesicular lesion
Subcorneal
pustular
dermatosis
Autoinflammation
and
autoimmunity
Autoimmune
thyroiditis
Chronic
thrombocytopenia
Noninflammatory
myopathy
Fluctuating
thrombocytopenia
Splenomegaly
Fluctuating
thrombocytopenia
Treatment IVIG
Fluconazole and
trimethoprim-
sulfamethoxazole
prophylaxis
IVIG
Fluconazole and
trimethoprim-
sulfamethoxazole
prophylaxis
Inhaler steroid and
salbutamol
IVIG
Trimethoprim-
sulfamethoxazole
prophylaxis 1
Colchicum-Dispert
IVIG
Trimethoprim-
sulfamethoxazole
prophylaxis 1
Colchicum-
Dispert
None IVIG
Fluconazole and
trimethoprim-
sulfamethoxazole
prophylaxis
IVIG, Intravenous immunoglobulin replacement; NA, not available/applicable; SDS, Standard deviation score; WISC-R, Wechsler Intelligence Scale for Children–Revised.
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TABLE II. Immunologic characterization of the patients
Family A B
Patient 1 2 3
Age at
evaluation
(y)
7 8 9 11 9 11 12 18
Hemoglobin
(g/dl)
11 10.6 12.2 10.3 9.5 10.3 9 5.83
Lymphocyte
count
(cells/mL)
2,300 (1,500-
7,600)
830 (1,500-
7,600)
1,910
(1,500-7,600)
1,920
(1,700-5,700)
3,810
(1,500-7,600)
4,540 (1,700-
5,700)
2,630 (1,700-
5,700)
3,000 (1,700-
5,700)
Neutrophil
count
(cells/mL)
4,600 18,020 2,200 3,810 16,160 19,370 4,580 10,900
Platelet count
(cells/mL)
63,000
(150,000-
450,000)
27,000
(150,000-
450,000)
55,000
(150,000-
450,000)
54,000
(150,000-
450,000)
389,000
(150,000-
450,000)
440,000 (150,000-
450,000)
277,000
(150,000-
450,000)
422,000
(150,000-
450,000)
MPV (fL) 10.1 10.9 13.7 12.2 8.2 8.3 9.1 8.17
IgG (g/L) 5.72 (without
substitution)
(4.11-14.35)
3.71 (without
substitution)
(4.11-14.35)
7.06 (IVIG
substitution)
(6.54-15.94)
10.40 (IVIG
substitution)
(6.54-15.94)
13.3 (without
substitution)
(6.54-15.94)
8.1 (IVIG
substitution)
(6.54-15.94)
13.6 (IVIG
substitution)
(6.98-11.94)
11.2 (without
substitution)
(5.84-14.86)
IgA (g/L) 1.95 (0.34-2.14) 1.09 (0.34-2.14) 0.31 (0.11-2.51) 0.99 (0.11-2.51) 1.57 (0.11-2.51) 1.49 (0.11-2.51) 1.19 (0.22-2.74) 0.98 (0.91-3.93)
IgM (g/L) 0.72 (0.15-1.15) 0.29 (0.15-1.15) 0.27 (0.13-1.45) 0.53 (0.13-1.45) 0.26 (0.13-1.45) 0.34 (0.13-1.45) 0.39 (0.19-0.99) 0.37 (0.32-2.23)
Response to
vaccination
antigens
Anti-rubella: 52 IU/mL (positive, N: >10 IU/mL)
Anti-tetanus: 5 IU/mL (positive, N: >0.1 IU/mL)
Anti-diphtheria: 1.61 IU/mL (positive, N: >1 IU/mL)
Anti-HBsAg: <5 mIU/mL (negative, N: >10 mIU/mL)
Anti-tetanus <0.1 IU/mL (negative, N: >0.1 IU/mL)
Anti-HBsAg: 5 mIU/mL (negative, N: >10 mIU/mL)
CD191 B cells
(cells/mL)
NA 100 (200-2,200) 170 (200-2,200) 190 (200-1,400) 60 (200-2,200) 164 (200-1,400) 112 (200-1,400) 5 (200-1,400)
CD31 T cells
(cells/mL)
NA 570 (1,000-
4,900)
1,490
(1,000-4,900)
1,474 (1,100-
4,100)
3,090 (1,000-
4,900)
2,670 (1,100-
4,100)
3,196 (1,100-
4,100)
1,743 (1,100-
4,100)
CD41 T cells
(cells/mL)
NA 340 (500-2,700) 760 (500-2,700) 705 (600-2,400) 1,780 (500-2,700) 1,596 (600-2,400) 1,838
(600-2,400)
976 (600-2,400)
CD81 T cells
(cells/mL)
NA 240 (300-2,100) 650 (300-2,100) 648 (400-1,500) 1,220 (300-2,100) 981 (400-1,500) 1,226 (400-1,500) 744 (400-1,500)
NK cells
(cells/mL)
NA 120 (200-900) 220 (200-900) 223 (200-1,000) 290 (200-900) 337 (200-1,000) 595 (200-1,000) 302 (200-1,000)
Neutrophil
function
(BURST
test)
Normal NA Normal
Other Anti-thyroglobulin and anti-TPO autoantibodies: positive
Cranial MRI: normal
Parahormone and growth hormone stimulation tests:
normal
Normal ranges are shown in parentheses. Normal range for cell types in children is according to Ikinciogullari et al,29 normal range for cell types in adults is according to
Coman-Bitter et al,30 normal range for immunoglobulins in children is according to Stiehm and Fudenberg,31 and normal range for immunoglobulins in adults is according to
Puissant-Lubrano et al.32
IVIG, Intravenous immunoglobulin replacement; MPV, mean platelet volume; MRI, magnetic resonance imaging; NA, not available/applicable; NK, natural killer; TPO,
thyroperoxidase.
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U-bottom 96-well plate, and counted with a Fortessa flow cytometer
(BD Biosciences). The proportion of migrating cells was normalized to the
initial input cell number.Expansion of T and B cells
Patient and healthy donor T cells were expanded by using a feeder cell
mixture, as previously described,26 and maintained in RPMI 1640 medium
containing L-glutamine (Gibco, Life Technologies, Grand Island, NY)
supplemented with 1% penicillin/streptomycin (Invitrogen, Carlsbad, Calif)
and 10% heat-inactivated human serum (all fromGibco). Culturing conditions
were 378C in a humidified 5% CO2 atmosphere. EBV-immortalized
B-lymphoblastic cell lines (B-LCLs) were generated by adding EBV viral
supernatant onto freshly isolated PBMCs. The following day, 1 mg/mLcyclosporin A was added to the cells, which were cultured in RPMI 1640
medium with L-glutamine supplemented with 1% penicillin/streptomycin
(Invitrogen) and 10% heat-inactivated FCS (Gibco, Life Technologies).Morphology and apoptosis of B-LCLs
Themorphology and F-actin content of B-LCLs was assessed on combined
B-cell receptor (BCR)/Toll-like receptor (TLR) stimulation. Eight-well slides
(ibidi, Martinsried, Germany) were coated with anti-IgA/IgG/IgM
(10 mL/mL; Abcam, Cambridge, United Kingdom) overnight at 48C. After
washing, cells were seeded in the presence of 5 mmol/L CpG ODN 2006
(InvivoGen, San Diego, Calif) and 1 mmol/L SiR-Actin (Tebu-bio, Le Perray-
en-Yvelines, France). After 3 hours, bright-field, total internal reflection
fluorescence (TIRF), and interference reflection microscopy (IRM) images of
live cells were acquired with a Nikon inverted spinning disk confocal
B C
3 4 5 6
20 21 21 23 23 26 5 6 7
12 13.7 10.5 12.5 14 NA 9.6 NA 9.1
2,480 (1,600-
2,500)
2,780 (1,600-
2,500)
1,170 (1,600-
2,500)
1,400 (1,600-
2,500)
1,180 (1,600-
2,500)
1,500 (1,900-
2,800)
1,360 (1,500-
5,200)
NA 1,600 (1,500-
7,600)
9,310 29,700 8,000 7,600 2,110 8,770 11,670 NA 14,830
108,000
(150,000-
450,000)
125,000
(150,000-
450,000)
120,000
(150,000-
450,000)
105,000
(150,000-
450,000)
49,000
(150,000-
450,000)
174,000
(150,000-
450,000)
213,000
(150,000-
450,000)
NA 191,000
(150,000-
450,000)
10.2 9.79 9.6 8.32 9.03 9.2 8.8 NA 9.2
10.3 (IVIG
substitution)
(5.84-14.86)
8.5 (IVIG
substitution)
(5.84-14.86)
6.96 (without
substitution)
(5.84-14.86)
10.0 (IVIG
substitution)
(5.84-14.86)
9.27 (IVIG
substitution)
(5.84-14.86)
15.3 (without
substitution)
(5.84-14.86)
5.45 (without
substitution)
(4.73-13.85)
NA 9.65 (without
substitution)
(4.11-14.35)
0.97 (0.91-3.93) 0.69 (0.91-3.93) 2.18 (0.91-3.93) 2.18 (0.91-3.93) 2.01 (0.91-3.93) 2.50 (0.91-3.93) 6.25 (0.39-1.47) NA 9.65 (0.34-2.14)
0.33 (0.32-2.23) 0.24 (0.32-2.23) 0.23 (0.32-2.23) 0.42 (0.32-2.23) 0.36 (0.32-2.23) 2.20 (0.50-2.60) 0.53 (0.20-0.92) NA 0.37 (0.15-1.15)
Anti-tetanus: 0.15 IU/mL (positive,
N: >0.1 IU/mL)
Anti-pneumococcus: 4 mg/L
(positive, N: >1.3 mg/L)
Anti-tetanus: 0.5 IU/mL (positive, N: >0.1)
Anti-pneumococcus: 16 mg/L (positive,
N: >1.3 mg/L)
NA Anti-tetanus: >5 IU/mL (positive, N: >0.1 IU/mL)
Anti-rubella: 15 IU/mL (Positive, N: 10-15 IU/mL)
Anti-HBsAg: 45 mIU/mL (positive, N: >10 mIU/mL)
25 (130-260) 28 (130-260) 7 (130-260) 14 (130-260) 12 (130-260) 41 (170-270) 53 (300-1,200) 89 (200-2,200) 60 (200-2,200)
1,959 (700-
2,100)
2,113 (700-
2,100)
506 (700-2,100) 882 (700-2,100) 732 (700-2,100) 1,351 (700-
2,100)
1,168 (1,900-
3,600)
1,355 (1,000-
4,900)
1,194 (1,000-
4,900)
967 (300-1,400) 1,029 (300-
1,400)
312 (300-1,400) 588 (300-1,400) 484 (300-1,400) 576 (300-1,400) 582 (600-2,000) 648 (500-2,700) 511 (500-2,700)
794 (200-900) 945 (200-900) 213 (200-900) 364 (200-900) 295 (200-900) 699 (200-900) 560 (300-1,300) 633 (300-2,100) 581 (300-2,100)
99 (90-600) 278 (90-600) 77 (90-600) 224 (90-600) 260 (90-600) 72 (90-600) 119 (200-1,200) 159 (200-900) 200 (200-900)
Normal Normal NA Normal
TABLE II. (Continued)
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PFAJFER ET AL 7microscope (Nikon, Tokyo, Japan) equipped with a back-thinned charge-
coupled device camera (Evolve, 512 3 512 pixels; Photometrics, Tucson,
Ariz), a temperature- and CO2-controlled chamber, and an oil immersion
3100/1.49 NA objective. The morphologic parameters of the acquired cells
were quantified with ImageJ software, applying masks to the bright-field im-
ages. Apoptosis of B-LCLs was measured on stimulation with 1.5 mL/mL
anti-IgA/IgG/IgM and 5 mmol/L CpG ODN 2006. At the indicated time
points, cells were stained on ice with Annexin V–APC (3 mL per 100 mL;
BD Biosciences) and propidium iodide (1.5 mL per 100 mL; BioLegend,
San Diego, Calif) in Annexin V binding buffer (eBioscience) for 5 minutes,
topped up with an additional 200 mL of binding buffer, and kept on ice for
acquiring by using flow cytometry. Gates were defined by means of
comparison with apoptotic control samples treated at 658C for 10 minutes.B-cell somatic hypermutation and class-switch
recombination
PBMCswere collected for patients and healthy donors, as described above.
RNA extraction was carried out according to the RNeasy Kit protocol
(Qiagen, Hilden, Germany). Elutionwas done twicewith 25mL of RNase-free
water. Two independent multiplex PCR reactions were performed by using
VH1-6 FR1 forward primers and IGHA or IGHG reverse primers,
respectively. The obtained PCR fragments were cloned into pGEM-t Easy
Vector (Promega, Madison, Wis), and sequencing of single clones was
performed on an ABI Prism 3130XL (Applied Biosystems, Foster City, Calif).
After demultiplexing the raw data, FASTA files were uploaded into the IMGT
High-V-Quest database, and the resulting files were analyzed by using the
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8 PFAJFER ET ALsomatic hypermutation (SHM) and class-switch recombination pipeline in
ARGalaxy. The clonality of the complementarity-determining region (CDR)
1–CDR3 region was analyzed by using Change-O. SHM analysis was done, as
previously described.27
Calcium flux experiments on supported lipid
bilayers
Calcium flux was assessed in expanded T cells confronted with stimulatory
glass-supported lipid bilayers (SLBs), as described previously,21 with the
modifications described below. Briefly, T cells (0.5-1 3 106) were loaded
with 5 mmol/L Fura-2 AM (Invitrogen) in complete RPMI 1640 medium for
30 minutes at 258C and then washed twice with 10 mL of imaging buffer
(13 HBSS [Gibco] supplemented with 1% FCS [Sigma, St Louis, Mo],
1 mmol/L MgCl2 and 1 mmol/L CaCl2). For imaging, cells were spotted
onto SLBs functionalized with OKT3-derived single-chain variable
fragments at indicated densities and intercellular adhesion molecule 1
(ICAM-1; 50 ng/well or approximately 100 ng/mL). SLB protein density
determination was performed, as previously described.28 Image acquisition
was performedwith a DMI4000Bmicroscope (LeicaMicrosystems) equipped
with a 320 objective (Leica 320 PH2) and an Andor iXon Ultra-8871
EM-CCD camera (Andor Technology, Belfast, United Kingdom) controlled
by Metamorph Imaging software (Molecular Devices, Eugene, Ore). Imaging
of Fura-2 (excitation, 340 nm and 380 nm; emission, 510 nm) was achieved
with the use of a fast external excitation filter wheel equipped with band
pass filters at 340 and 380 nm (Leica Fura EX) and a filter cube consisting
an emission band pass filter at 520 nm (Fura-2 Leica EM520/36, DC:409).
Fura-2 images were collected at intervals of 30 seconds over approximately
10 minutes. Intracellular calcium dynamics were determined ratiometrically
from Fura-2 emissions acquired through 340 and 380 nm of excitation by
using the open-source Fiji software package. Ratios of Fura-2 emissions
were normalized with regard to the first acquired Fura-2 emission ratio
determined for nonactivated T cells, which had not yet established productive
contacts with the SLB. T cells contacting SLBs featuring ICAM-1 alone were
recorded for each healthy donor and patient and served as negative controls.
Statistical analysis
Statistical analyses were performed with GraphPad software. Statistical
significance was determined by performing 2-tailed nonparametric t tests.
Resulting P values are indicated as follows: ns, P > .05, *.01 < P < .05,
**.001 < P < .01, and ***P < .001.
RESULTS
Clinical characteristics of the patients
Here we studied 6 patients from 3 consanguineous pedigrees
experiencing skin ulcerations, multiple respiratory tract and other
infections, intellectual impairment, and in 3 cases stomatitis
inflammation (Fig 1,A-F, and Tables I and II).29-32 A detailed case
report is provided in a separate document (see the Methods
section and Tables E1 and E2 in this article’s Online Repository
at www.jacionline.org).Identification of novel WDR1 gene mutations in 3
families, resulting in reduced WDR1 expression
Given the consanguineous background of the 3 families, the
shared phenotypic traits within the patients, and the absence of
clinical signs of immunodeficiency in the unaffected siblings and
parents (with the exception of family C), we suspected a common
autosomal recessive disease trait. We performed whole-exome
sequencing to identify the underlying genetic disease cause.
Patient P1 (family A) was found to carry a homozygous missense
variant on chromosome 4, 10099458: G>C (hg19 build 137;
NM_017491.3: c.C435G, p.His145Gln) in WDR1 (Fig 1, G).Patient P2 (family B), as well as patients P3 and P4, were
found to carry a homozygous missense variant (c.A1715T,
p.Asp572Val) in WDR1 (Fig 1, H). Patient P6 (family C) was
found to carry the same mutation as identified in family B
(c.A1715T, p.Asp572Val), and patient P5, the mother of P6,
was found to be a heterozygous carrier of the p.Asp572Val
mutation together with another heterozygous variant
(c.G1501A, p.Gly501Ser; Fig 1, I). These WDR1 gene variants
have not been observed in heterozygous or homozygous form in
several human genetic variation databases, including the 1000
Genomes Project and the Exome Aggregation Consortium. In
addition, the heterozygous carriers did not show any symptoms.
The variant found in family A (H145Q) was predicted to be
benign and tolerated, with a CADD score of 13.3. The variant
identified in families B and C (D572V) was predicted to be
damaging and deleterious based on PolyPhen-2 and SIFT
predictors for the corresponding protein function, with a CADD
score of 28. The heterozygous variant identified in patient P5
(G501S) was predicted to be damaging and deleterious, with a
CADD score of 26.7.
The WDR1 gene variants found in the 3 families segregated
perfectly with the disease under the assumption of autosomal
recessive inheritance (see Fig E1 in this article’s Online
Repository at www.jacionline.org). Although variants in
additional genes also segregated within the individual
families (see Table E3 in this article’s Online Repository at
www.jacionline.org), they were disregarded as being causative
because they could not be related to the immunodeficiency status
of the patients. Additionally, the striking similarities between the
clinical phenotypes in the 3 families pointed to theWDR1 variants
as the common cause of the immunopathology. The 3 identified
mutations are located in coils between antiparallel b-sheet
repeats, which might affect the 3-dimensional blade structure of
WDR1 and its overall stability (Fig 1, J).
We analyzed WDR1 expression in the patients’ PBMCs by
using Western blotting. The newly identified mutations
were associated with near-absent levels of WDR1 expression
(Fig 1, K). However, we observed variable residual WDR1
expression in both expanded T cells from the patients, suggesting
that lymphocyte activationmight stimulate or stabilize expression
of the WDR1 variants (see Fig E2, A, in this article’s Online
Repository at www.jacionline.org).
Together, our data demonstrate that the newly identifiedWDR1
mutations lead to amarkedWDR1 expression defect in peripheral
blood cells from the patients, reinforcing the link of causality
between the WDR1 mutations and the immunopathology
affecting the patients.Neutrophil and monocyte defects associated with
WDR1 mutations
On blood smear examination, we detected abnormal herniation
of neutrophil nuclear lobes (data not shown). This characteristic
observation is in line with the recent identification ofWDR1 mu-
tations in immunodeficient patients for whom neutrophil nuclear
herniation and associated defects were identified as a hallmark of
the disease.4 Neutrophils were purified and stained with Phalloi-
din and 49-6-diamidino-2-phenylindole dihydrochloride to
further characterize the morphologic defects associated with
mutant WDR1. Approximately half of the neutrophils from the
patients with WDR1 mutations had aberrant morphology (Fig 2,
FIG 2. Effect ofWDR1 variants on neutrophils andmonocytes.A, Representative picture of neutrophils from
a healthy donor and patient P3 deposited on fibronectin or fibronectin plus fMLP. Morphologies of
fMLP-stimulated neutrophils (36 from a healthy donor and 55 from patient 3) classified as normal (light
gray), nuclear herniations (dark gray), or complex aberrations (black). B, Five-year longitudinal analysis
of neutrophil absolute counts in patients P1 to P4. The normal range is indicated in gray. C, Migration of
neutrophils from 2 healthy donors and patients P1 to P5 in response to indicated concentrations of fMLP.
Data correspond to 1 experiment of 2 performed. D, Representative picture of monocytes from a healthy
donor and patient P3 on spreading over fibronectin or fibronectin plus LPS. E, Number of actin dots
quantified in 30 monocytes from a healthy donor and patient P3. Data correspond to 1 experiment of 2
performed. F, The surface covered by monocytes spreading over fibronectin (gray and light red dots) or
fibronectin plus LPS (black and red dots) was quantified in 60monocytes from 2 healthy donors and patients
P1 to P4. Data pertaining to morphologic aberrations in neutrophils were confirmed in independent
experiments performed on a second blood sampling from patients P1 to P4. HD, Healthy donor.
**.001 < P < .01, and ***P < .001.
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clear lobes protruding from the cell body or a loss of nuclear
integrity, as revealed by spread 49-6-diamidino-2-phenylindole
dihydrochloride staining. These morphologic aberrations were
associated with dissolution of cortical actin and abnormal accu-
mulation of filamentous actin toward the cell center, as deter-
mined based on F-actin staining. Therefore our
immunofluorescence data suggest that loss-of-function mutations
in WDR1 affect actin turnover, thereby leading to both a weak-
ening of the cell cortex and accumulation of cytoplasmic actin
structures. This process either pushes nuclear lobes out of the
cell body or more profoundly disrupts nuclear integrity. These
morphologic defects were not associated with reduced numbers
of circulating neutrophils. On the contrary, patients had normal
to increased neutrophil counts in peripheral blood (Fig 2, B).
We further explored how such morphologic aberration might
affect the capacity of neutrophils to survive and migrate.Neutrophils from the patients with WDR1 mutations did not
consistently display accelerated loss of mitochondrial membrane
potential (see Fig E3, A, in this article’s Online Repository at
www.jacionline.org) or increased apoptosis (see Fig E3, B and
C). However, a transwell assay revealed impaired migration of
neutrophils from the patients with WDR1 mutations in response
to fMLP (Fig 2, C). Therefore our data reinforce the notion that
biallelic WDR1 mutations in human subjects are associated
with a characteristic phenomenon of neutrophil herniation, with
defective migration toward fMLP.
We next investigated whether morphologic aberrations would
apply to monocytes. On blood isolation and seeding over
fibronectin-coated slides, monocytes from the patients with
WDR1mutations emitted actin dots oriented toward the substrate,
which were not detectable in normal monocytes (Fig 2,D). These
structures are reminiscent of actin-rich podosomes, which are
assembled in macrophages and monocyte-derived dendritic
FIG 3. Effect ofWDR1 variants on T-cell activation and function. A, Representative flow cytometric analysis
of T-cell subsets in PBMCs from a healthy donor and patients P1 and P2. B, Flow cytometry–based
quantification of the indicated T-cell subsets in PBMCs from 3 healthy donors and the 6 patients. Data
correspond to 1 experiment of 2 performed for patients P5 and P6 and of 1 experiment for patients P1 to
P4. C, Representative images of F-actin staining in primary T cells from a healthy donor and patients P2
(upper panels) and P3 (lower panels) spreading over coated anti-CD3 antibody. Comparable morphologic
aberrations were observed in an experiment performed on a second blood sampling from patients P1 to
P4. D, T-cell surface on spreading over fibronectin (gray and light red dots) or anti-CD3 antibody (black
and red dots) in 2 healthy donors and patients P1 to P4. Ten to 60 T cells were analyzed per condition.
Data correspond to 1 experiment of 2 performed. E, Calcium influx in expanded T cells from 2 healthy
donors and patients P1 to P4 stimulated over a lipid bilayer presenting ICAM-1 and anti-CD3 antibodies.
Data correspond to 1 experiment of 2 performed. HD, Healthy donor. *.01 < P < .05, **.001 < P < .01, and
***P < .001.
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LPS stimulation. Evidently, patients’ monocytes emitted a signif-
icantly higher number of actin dots when compared with control
monocytes on LPS stimulation (Fig 2, E). These observations are
in agreement with previous findings of increased podosome as-
sembly in dendritic cells from patients with WDR1 mutations.5
In parallel, we measured an increased ability of patients’ mono-
cytes to spread over fibronectin spontaneously or on LPS stimula-
tion (Fig 2, F). In conclusion, monocytes isolated from the blood
of patients with WDR1 mutations displayed increased basal and
LPS-driven spreading associated with podosome-like F-actin
structures.TCR activation in WDR1-mutated T lymphocytes
In view of the pleiotropic expression of WDR1, we reasoned
that WDR1 mutations might also affect functional integrity of
lymphoid cells. We first investigated the T-cell compartment of
patients through phenotypic characterization of peripheral blood
T-cell subsets. Although normal proportions of T cells belonging
to the CD41, CD81, naive, central memory, effector memory, and
stem memory subsets were detected, follicular helper T (Tfh)
cells were present in a reduced proportion in all 6 patients
(Fig 3, A and B, and see Fig E2, B). We then investigated actin
cytoskeletal organization in T cells from patients P1 to P4 on
interaction with anti-CD3 antibody–coated slides. Somewhat
FIG 4. Effect ofWDR1 variants on the B-cell compartment.A,Representative flow cytometric analysis of B-cell
subsets in PBMCs froma representative healthy donor andpatients P1 andP2.B,Absolute numbers of periph-
eral B cells (upper left panel, mean 6 SD of 3 values, normal range in gray) and proportion of CD191 B-cell
subsets from 2 healthy donors and the 6 patients: transitional B cells (CD101CD381, upper right panel),
IgM/Dmemory B cells (CD271IgD1, lower left panel), and IgGmemory B cells (CD271IgD2, lower right panel).
Data correspond to 1 experiment of 2 performed for patients P5 and P6 and of 1 experiment for patients P1 to
P4.C,Analysis of B-cell clonal diversity in PBMCs from 8 healthy donors and patients P1 to P4. Clonal diversity
is represented as plots depicting the relative size of the largest clone and the proportion of unique clonal reads
for all sequences, IgA sequences, and IgG sequences (upper plots). SHMevents in B cells fromhealthy donors
and patients P1 to P4 (lower plots). D, Immunohistology of bonemarrow from an age-matched healthy donor
and patients P1 and P2. E, Immunohistologic staining for hematoxylin and eosin (H&E), CD71, CD79a, or
terminal deoxynucleotidyl transferase (TdT) in bone marrow from patient P1. HD, Healthy donor.
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12 PFAJFER ET ALreminiscent of what we observed in the monocytes, the tested
T cells from patients displayed aberrant actin meshwork
organization and increased spreading (Fig 3, C and D). The
abnormal actin structures identified in WDR1-mutant
lymphocytes included actin arcs, actin spikes, and filopodia,
which were described to be dependent on formin activity.34
This suggests that the defect in actin turnover associated with
WDR1 deficiency results in increased assembly of structures
that might depend on formin rather than Arp2/3 activity.
We then tested which aspects of TCR-mediated activation
might be controlled by WDR1. T cells derived from all tested
patients (P1-P4) displayed a diminished calcium response, which
was reduced in amplitude at intermediate and high densities of
stimulatory anti-CD3 antibodies (Fig 3, E). This indicates a role
for WDR1 in tuning TCR-proximal signaling. Differently, the
later event of TCR internalization was not affected in WDR1
mutant T cells from patients P1 to P4 (see Fig E2, C). A recent
study reported a defect in anti-CD3 antibody–evoked T-cell
proliferation in a patient carrying a WDR1 mutation.5 Our
analysis of T-cell proliferation from peripheral blood
collected at different time points showed inconsistent anti-CD3
antibody–evoked proliferation rates, varying from reduced to
normal values (see Fig E2, D). In addition, the WDR1 mutations
affected neither the ability of T cells expanded from the blood
of patients P1 to P4 to migrate in response to CXCL12 (see
Fig E2, E) nor the capacity of purified CD81 T cells to kill target
cells (see Fig E2, F). Together, our data suggest that WDR1
deficiency only mildly affects the development and TCR
activation of T lymphocytes.Abnormal B-cell development in patients with
WDR1 mutations
Although WDR1 mutations had only a limited effect on
production of mature T cells in the periphery, we observed a
marked phenotype in the B-cell compartment. Indeed, low
B-cell counts were detected in the peripheral blood in all patients
reported here (Fig 4, A and B, and see Fig E4, A, in this article’s
Online Repository at www.jacionline.org). Residual peripheral
B cells were abnormally skewed toward the transitional B-cell
stage in all 6 patients. Except for patient 5, the proportions of
IgM nonswitched (CD271IgD1) and IgG class-switchedmemory
(IgD2CD271) cells among the B-cell subset were significantly
reduced. This phenotype points toward a defect in B-cell
development. Indeed, there was a large accumulation of
peripheral blood B cells with a CD101CD381 phenotype, which
is consistent with them being transitional B cells (ie, recent bone
marrow emigrants; Fig 4, A and B, and see Fig E4, A).
The paucity of memory B cells might reflect a defect during the
steps of class-switch recombination or SHM.
To explore this possibility, we sequenced the CDR1-CDR3
region and analyzed the clonality of the IGHA or IGHG regions.
The BCR repertoire of the 4 tested patients withWDR1mutations
was of a restricted size, with P3 and P4 harboring an extremely
clonal repertoire (Fig 4, C). These 2 patients are the oldest
(21 and 24 years compared with 11 and 12 years for P1 and
P2), which might indicate that the size of the BCR repertoire
diminished with age. We further detected decreased SHM in
B cells from the patients with WDR1 mutations (Fig 4, C).
The mechanisms underlying this observation could include
CD41 T-cell lymphopenia, especially Tfh cells, impaired T-cellproliferation, or an intrinsic B-cell defect. However, SHM target-
ing (AID and Pol h motifs) and repair (transition/transversion
mutation at the AT or GC locations) were normal (see Fig E4,
B). This suggests no defect in the error-prone repair of mismatch
repair or base excision repair that is used during SHM. The
median CDR3 length was higher, but this is probably not caused
by an increase in JH6 (the longest JH gene) or an increase in the
number of N-nucleotides, but the number of deletions is lower in
the patients (see Fig E4, C). The median CDR3 length in the
switched memory B cells is higher in patients compared with
control subjects, suggesting that selection for B cells with shorter
CDR3 length might be impaired. The abnormal peripheral B-cell
compartment might originate from an early bone marrow defect.
Bone marrow biopsy specimens were available from patients P1
and P2, which allowed us to perform histologic analysis. In
both patients the marrow was normocellular, with a usual
topographic arrangement of slightly disrupted erythropoietic
(Fig 4, D and E, and see Fig E5, A and B, in this article’s Online
Repository at www.jacionline.org) and myeloid precursor cells.
Megakaryocytes were regularly distributed and inconspicuous.
Only a few lymphocytes were discerned morphologically.
Immunohistologically, most lymphocytes were CD31 T cells
with only singular CD201/CD79a1/PAX-51/CD221 B cells
intermingled. However, the fewB cells weremostlymature, given
the fact that they were terminal deoxynucleotidyl transferase and
CD10 negative. Comparedwith the frequency of normal B cells in
age-matched control bone marrow biopsy specimens, the very
low frequency of CD201 cells points to a severe reduction of
bone marrow B-cell precursors.
We then reasoned that the paucity of B-cell precursors in the
bone marrow and the reduced ability of the B cells that reach the
periphery to differentiate and generate a diversified BCR
repertoire could result either from intrinsic BCR signaling
defects, motility defects affecting tissue localization and homing,
or reduced survival. To test these possibilities, we used B-LCLs
generated from the few B cells collected from the peripheral
blood of the patients. After stimulation with anti-IgA/IgG/IgM
and CpG, B cells from patients with WDR1 mutations displayed
increased adhesion, as determined based on the proportion of
cells spreading (Fig 5, A). Strikingly, the morphology of the
patients’ B cells spreading over anti-IgA/IgG/IgM and CpG was
characterized by an increased emission of multiple thin
protrusions. In agreement with the role of WDR1 in actin
turnover, examination of the actin cytoskeleton by using TIRF
microscopy of cells prestained with SiR-actin revealed an
increased density of polymerized actin at the ventral plane of
the cells. Accordingly, the cells carrying WDR1 mutations
displayed a very tight adhesion to the substratum, as observed
by using IRM. This propensity of the WDR1-mutated B cells to
spread resulted in a much wider surface and perimeter than
control cells and a reduced circularity (Fig 5, B).
We then assessed the ability of the B-LCLs from patients with
WDR1 mutations to migrate directionally. When exposed to a
CCL19 gradient, the WDR1-mutated B cells migrated normally
along the gradient, as assessed by using the forward migration
index (see Fig E6 in this article’s Online Repository at
www.jacionline.org). This suggests that theWDR1-related defect
of B cells is restricted to the BCR.
We next investigated whether these B cells might be
abnormally prone to apoptosis on BCR/TLR stimulation.
B-LCLs from patients P2 and P3 displayed spontaneous
FIG 5. Effect ofWDR1 variants on B-cell activation and apoptosis. A, Representative pictures of B-LCLs from
a healthy donor and patient P1 on spreading over anti-IgA/IgG/IgM plus CpG. Bright-field and TIRF imaging
of F-actin (SiR-Actin) are shown in parallel. The pictures stem from 1 experiment of 2 performed. Data
correspond to 1 experiment of 2 performed. B, Morphologic parameters of B-LCLs from a healthy donor
and patient P1 on spreading over anti-IgA/IgG/IgM plus CpG. C, Apoptosis in B-LCLs from 2 healthy donors
and patients P1, P2, and P3, as determined by staining for Annexin V and propidium iodide, after 0, 12, 24, or
36 hours of BCR/TLR stimulation. Data correspond to 1 experiment. HD, Healthy donor. ***P < .001.
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14 PFAJFER ET ALapoptosis, as highlighted by the high proportion of late apoptotic
cells (propidium iodide–positive Annexin V1) before stimulation
(Fig 5, C). The proportion of late apoptotic cells further increased
on BCR/TLR stimulation. Although B cells from patient P1
appeared less affected, we noted an increased rate of both early
and late apoptotic cells after 24 hours of stimulation.
Collectively, these data highlight the key role of WDR1 in the
development and activation of B cells. They further indicate that
WDR1 is required for BCR-mediated activation and survival.DISCUSSION
Here we identified 6 patients from 3 consanguineous families
carrying novel WDR1 biallelic missense mutations leading to
defective expression of WDR1 in immune cells. In addition to
recently described alteration of myeloid cell morphology and
function in the context of WDR1 deficiency,4,5 our study unravels
a previously unappreciated role of WDR1 in lymphocyte
activation and development.
The discovery of a number of PIDs caused by deficiency or
molecular alteration of actin cytoskeletal remodeling proteins has
allowed us to gain insight into the key role of actin cytoskeletal
dynamics in supporting immune cell function.3 In this context the
characterization of patients carrying WDR1 mutations provides a
unique insight into a yet poorly studied facet of actin cytoskeletal dy-
namics in control of leukocyte development, activation, and function.
A hallmark of WDR1-mutated leukocytes appears to be the
assembly of aberrant actin structures. This applied to T- and
B-cell immunologic synapses, as well as to neutrophils and
monocytes. Of interest, these structures were specific to each
cell subset and were interfering with distinct cellular processes.
WDR1-mutated lymphocytes displayed defective activation or
survival on antigen receptor triggering, which appeared to be
related to abnormal actin turnover at the synapse. Monocytes
displayed aberrant spreading in relationship with the assembly
of numerous podosome-like structures. Neutrophils appeared to
be affected predominantly in their migratory capacity as a
probable consequence of the loss of their morphologic integrity.
These observations point to a rather selective role of WDR1 in
sustaining specific actin-related processes in distinct leukocytes.
The most severe cellular defect identified in our cohort of
patients with WDR1 mutations was a profound B-cell
lymphopenia mirrored by low B-cell precursor counts in the
bone marrow. In apparent contrast, the few B cells detected in
bone marrow were mature B cells, whereas the peripheral
B-cell compartment was skewed toward an immature transitional
B-cell stage. This might result from a premature release of
immature B cells from the bone marrow, as shown in patients
with Wiskott-Aldrich syndrome (WAS), another disorder of the
actin cytoskeleton.35 Therefore, for the first time, our study
identifies WDR1 as a key actin regulator required for B-cell
differentiation. Applying TIRF and IRM microscopy to patient-
derived B cell lines, we further observed aberrant activation on
BCR/TLR stimulation, leading to multiple actin-rich filopodia
associated with elongated B-cell synapse morphology. This is
in line with previous studies showing that BCR stimulation
depends on actin depolymerization36 and that cofilin-evoked actin
severing is key to BCR-induced synapse formation.37 The
prominent effect of WDR1 deficiency on development of the
B-cell compartment might be explained by a role in tonic BCR
signaling, a process that depends on actin dynamics and is crucialfor the survival of developing B cells.38 Indeed, we identified an
increased apoptosis rate in B-LCLs derived from patients with
WDR1 mutations on BCR stimulation. We suspect that the
B-lymphocyte defects associated with WDR1 deficiency might
underlie some of the clinical manifestations, in particular the
recurrent infections.
The consequences of the identified WDR1 mutations on
generation of the T-cell compartment appeared less prominent
than on generation of the B-cell compartment. Thus, with the
exception of Tfh cells, normal proportions of the main T-cell
subsets were present in the peripheral blood of the patients
from our cohort. The selective reduction in numbers of Tfh cells
is likely a consequence of the B-cell deficiency because Tfh cells
require B cells for their differentiation and survival.39 On
stimulation with immobilized anti-CD3 antibodies, mature T
cells from the patients displayed increased spreading and aberrant
actin-rich structures that most probably result from a defect in
actin turnover. Such a defect might affect predominantly
Arp2/3-driven actin branching and lamellipodia assembly by
limiting the availability of actin monomers and capped actin
oligomers. In contrast, formin-driven actin filament elongation
might be affected to a lesser extent, and its activity would become
dominant over that of Arp2/3.
In agreement with this hypothesis, we observed aberrant
assembly of long actin filaments, either organized radially and
pointing outward or organized as arcs forming a circular belt
around the synapse. In agreement with those observations,
activation of patients’ T cells over a membrane bilayer presenting
recombinant ICAM-1 and anti-CD3 antibodies resulted in reduced
calcium influx. However, WDR1 deficiency was not consistently
associated with reduced anti-CD3–evoked T-cell proliferation,
pointing to a rather mild role in TCR-driven activation compared
with other PID-associated actin regulators, such as Wiskott-
Aldrich syndrome protein (WASP) or dedicator of cytokinesis
8.40,41 Coronin 1A–mediated actin depolymerization has been
shown to facilitate lytic granule delivery in natural killer cells.42
In our study, however, the identified WDR1 mutations did not
appear to cause a defect in T cell–mediated cytotoxicity in
expanded peripheral blood T cells. These observations call for a
further exploration of the molecular mechanisms controlling actin
depolymerization in the context of the cytotoxic activity of natural
killer and CD81 T cells.
Our report expands the phenotypic spectrum of WDR1
deficiency, which comprises marked defects of both innate and
adaptive immunity, resulting in severe autoinflammation,
predisposition to autoimmunity, and compromised B-cell
function. Different from WASP deficiency,43 the prototypical
actin-related PID, thrombocytopenia was inconsistent and
platelet volume was normal in patients with WDR1 mutations.
Eczema, a typical manifestation of WAS, was also absent in these
patients. However, the recurrent skin infections were reminiscent
of those observed in patients with WAS. The characteristic auto-
inflammatory manifestations of the patients with WDR1
mutations are distinct from those of patients with WAS, whereas
the autoimmune clinical presentation overlaps between the 2
disease entities. Although this has not been reported yet, it
appears likely that WDR1 deficiency is also associated with a
greater risk of malignancy, given dysregulated actin
polymerization reminiscent of the relatively high risk of
myelodysplasia/acute myeloid leukemia in X-linked neutropenia
caused by gain-of-functionmutations in patients withWAS,44 and
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general.45 On that basis, at least for the more severely affected
patients, allogeneic hematopoietic stem cell transplantationmight
be a feasible and rational approach.
Another clinical feature consistently observed in the patients
with WDR1 mutations was mild-to-moderate intellectual
disability. Gene variant analysis did not reveal any additional
variant that would be shared by the patients presenting with
intellectual disability and that might be related to such a clinical
presentation. Chronic inflammation or repeated hospitalization
periods might have contributed to intellectual disability. Given
the pleiotropic expression of WDR1, its deficiency in the central
nervous system might also result in neuronal defects. The
potential role of WDR1 in neuronal tissues will deserve further
investigation in the future.
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Key messages
d Deficiency of the actin regulator WDR1 in human
subjects is associated with a paucity of B-cell progenitors
in the bone marrow and lack of switched memory B cells
in the periphery.
d WDR1 missense mutations lead to aberrant assembly of
both T- and B-cell immunologic synapses.
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METHODS
Case reports
Patient P1 (8 years old, male sex) born to consanguineous parents was
admitted to the hospital with fever, diarrhea, aphthous stomatitis, and
pneumonia at 8 years of age. Past medical history revealed that he had
recurrent fever with vomiting, diarrhea, aphthous stomatitis, and hypokalemia
occurring every 4 to 6months, and although anti-thrombocyte antibodies were
not studied, he was given a diagnosis of chronic idiopathic thrombocytopenic
purpura at 2.5 years of age. On physical examination, mild intellectual
disability and muscle weakness with positive Gowers sign were noted.
Laboratory investigations showed chronic thrombocytopenia and an acute
decrease in lymphocyte counts with increased neutrophil counts and
acute-phase reactants during febrile episodes, which were triggered by
infections every 4 to 6 months. Candida albicans was isolated from his
aphthous lesions. Low IgG levels with B-cell lymphopenia were observed
(Table II). Anti-rubella, anti-tetanus, and anti-diphtheria antibodies
were positive, and results for anti-HB antibodies were negative.
Anti-thyroglobulin and anti-TPO autoantibody results were also positive. At
age 8 years, the Wechsler Intelligence Scale for Children–Revised test
performed for evaluation of mental development and revealed a verbal IQ
score of 72, a performance IQ score of 84, and a total IQ score of 75. Cranial
magnetic resonance imaging results were normal, and results of muscle biopsy
was consistent with noninflammatory myopathy. During follow-up, he
responded well to fluconazole and trimethoprim-sulfamethoxazole
prophylaxis with intravenous immunoglobulin replacement. The patient is
currently stable and is being evaluated for bone marrow transplantation.
Patient P2 (12 years old, female sex) was admitted to the hospital with
fever, growth retardation, and finger abscess at age 8 years. Past medical
history was significant for recurrent pneumonia, bronchiectasis, aphthous
stomatitis, and viral encephalitis. Having consanguineous parents, her family
history revealed that she had 2 brothers with the same symptoms (Fig 1, E).
She exhibited dysmorphic facial features, including frontal bossing,
hypertelorism, and wide nostrils. Severe growth retardation was noted on
physical examination, but growth hormone levels were normal.
Leukocytosis and anemia were detected by using a complete blood count.
Immunophenotyping revealed B-cell lymphopenia. The immunoglobulin
levels were within age references (Table II). Prophylactic antibiotics and
intravenous immunoglobulin replacement were initiated because she had
severe recurrent infections at age 9 years. During follow-up, she had multiple
episodes of hospitalizations and hepatosplenomegaly and lymphadenopathies
with increased acute-phase reactant levels (see Table E2). A corresponding
biopsy revealed reactive lymphoproliferation. Currently, she receives
intravenous immunoglobulin and prophylactic antibiotics with apparently
milder symptoms with growing age.
Patients P3 (21 years old, male sex) and P4 (24 years old, male sex) are
brothers of P2. P3 was evaluated at age 18 years at the dermatology unit
because of disseminated ulcerated lesions in the lower extremities that
appeared 7 years previously after an episode of trauma. He had facial cystic
acnes, a short stature, and difficulty in communication. Skin biopsy was
compatible with pyoderma, but results of pustule cultures were negative.
Laboratory assessment showed low IgM levels, B-cell lymphopenia,
persistent leukocytosis with neutrophilia, high C-reactive protein and serum
amyloid A levels (see Table E2), and fluctuating thrombocytopenia (Table II).
Thorax computed tomography revealed bronchiectasis (data not shown). After
starting regular intravenous immunoglobulin and Colchicum-Dispert, skin
lesions improved, as did facial acne. P4 was admitted to the dermatology
department at age 22 years with disseminated ulcerating purple-colored
lesions causing pruritus developing on the tibial area 7 years before after
trauma. Multiple cystic acne was also present on the face. Biopsy from the
lesions revealed Pyoderma gangrenosum, and cultures were negative for
bacteria and fungi. Bronchiectasis was detected on thorax computed
tomography. He had the same laboratory abnormalities as his younger brother,
lymphopenia, and persistent leukocytosis with polymorphonuclear
leukocyte increase. Fluctuating thrombocytopenia with large platelet volume
was recorded. Immunologic assessment revealed low B-cell numbers. Low
IgM and IgG2 levels were detected (Table II). He had persistent C-reactive
protein and serum amyloid A increases (see Table E2). Multiple antibiotic
courses and dressings with intravenous immunoglobulin were administered.
After beginning regular intravenous immunoglobulin (500 mg/kg) and
Colchicum-Dispert, lesions were alleviated.
Patient P6 (7 years old, female sex) was born to consanguineous parents.
She presented with recurrent febrile episodes every 1 to 2 months after a
respiratory tract infection, together with generalized vesiculopustular lesions.
Dermatologic evaluation and subsequent biopsy revealed subcorneal pustular
dermatosis. She also had recurrent aphthous stomatitis and pneumonia, during
which levels of acute-phase reactants remained high. Immunologic evaluation
was significant for high IgA levels and low B-cell counts. She had generalized
necrotic dermal lesions during the disease course. We lately discovered that
her mother (patient P5 [26 years old, female sex]) had similar symptoms as her
daughter. She experienced recurrent aphthous stomatitis, skin abscesses, and
pneumonia.
Neutrophil mitochondrial membrane potential
Neutrophils were isolated from peripheral blood and cultured at low
density in complete RPMI medium. As a measure of mitochondrial fitness,
dissipation of its membrane potential was monitored by loss of JC-1
mitochondrial aggregates (red channel; excitation/emission, 535/590 nm)
and a shift toward its monomeric cytosolic form (green channel;
excitation/emission, 485/530 nm). Neutrophils were loaded with JC-1 dye
(3.5 mmol/L; Life Technologies) at 378C for 15 minutes, washed with PBS,
and analyzed by using flow cytometry at the indicated time points. Gates were
applied on intact and single cells based on forward- and side-scatter features.
Neutrophil apoptosis
Apoptosis was measured in neutrophils on spontaneous progression of
cell death. At the indicated time points, cells were stained on ice with Annexin
V–APC (3mL per 100mL; BDBiosciences) and propidium iodide (1.5mL per
100mL; BioLegend) in Annexin V binding buffer (eBioscience) for 5minutes,
topped up with an additional 200 mL of binding buffer, and kept on ice for
acquiring by means of flow cytometry. Gates were defined by comparing with
apoptotic control samples treated at 658C for 10 minutes.
WDR1 expression in expanded T cells
Expanded T cells from patients and healthy donors were lysed in 100mL of
RIPA buffer. WDR1 expression was analyzed as described in the main
Methods section.
TCR downregulation
P815 cells were coatedwith OKT3 at the indicated concentrations. CD81T
cells were purified with immunomagnetic beads and incubatedwith P815 cells
at a 1:2 ratio for 4 hours. Cells were then stained with APC-H7–conjugated
anti-CD3 and FITC-conjugated anti-TCR antibodies (BD Biosciences) for
30 minutes at 48C. Expression of TCR at the CD81 T-cell surface was
analyzed by using a Fortessa flow cytometer (BD Biosciences) and FlowJo
software.
T-cell proliferation
PBMCs were labeled with eFluor 450 violet proliferation dye (BD
Biosciences), according to themanufacturer’s instructions. T-cell proliferation
was assessed after 72 hours of stimulation with either soluble anti-CD3
antibody (1 mg/mL, clone OKT3; eBioscience) plus anti-CD28 antibody
(1 mg/mL, clone CD28.2; eBioscience) or anti-CD3/CD28 antibody–coated
Dynabeads (Sigma-Aldrich). Dilution of the proliferation dyewas recorded on
a BD Fortessa cytometer and analyzed with FlowJo X software.
T-cell migration
Ninety-six-well transwell plates (5-mm pore size; Corning) were used to
assess T-cell migration in response to CXCL12. Expanded T cells were
harvested and resuspended in serum-free RPMI 0.5% BSA medium at
0.5 3 106 cells/mL. Fifty microliters of cell suspension was loaded on the
top of the transwell filter, whereas 150 mL of CXCL12 (PeproTech, Rocky
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Hills, NJ) solution was added to the lower chamber at the indicated
concentrations. After 4 hours of incubation at 378C, transmigrating cells
were collected and analyzed as described in the main Methods section.
T cell–mediated cytotoxicity
Green fluorescent protein–expressing P815 target cells pretreated with
aphidicolin (Sigma-Aldrich) to prevent proliferation were coated with OKT3
at the indicated concentrations to assess CD81 T-cell cytotoxic function.
CD81 T cells purified with immunomagnetic beads (MagniSort
Human CD81 T-cell Enrichment Kit) were added to the green fluorescent
protein–P815 target cells at a ratio of 1:1 for 4 or 24 hours, as indicated. After
incubation, 150 mL of the respective cell suspensions was transferred to a
96-well plate, and 50 mL of a 10% 7-aminoactinomycin D solution
(BD PharMingen) was added to each well. Analysis of residual target cell
numbers was performed by using a Fortessa flow cytometer equipped with
an automated plate reader device (BD Biosciences).
Chemotaxis of B-LCLs
Cells (105 B-LCLs in 6 mL of culture medium) were loaded into the central
transversal channel of Ibitreat 3D Chemotaxis m-slides (ibidi), coated with
5 mg/mL fibronectin, and incubated at 378C for 30 minutes to allow cell
attachment. A CCL19 gradient (0-200 ng/ml) was created, according to the
manufacturer’s instructions. Additional slides were prepared in parallel with a
10% dextran-FITC solution to verify gradient linearity and stability. Analysis
of fluorescence intensity profiles showed that linear gradients were established
within 3 hours and were stable over 24 hours. Slides were positioned in an
Apotome microscope (Zeiss) equipped with a 35/0.15 NA objective and with
controlled temperature and CO2 conditions. Recording of cell migration was
initiated 5 hours after seeding and lasted for 14 hours at a rate of 1 image every
minute. Obtained images were treated and binarized by using Image J software,
and migration tracks were obtained by using the TrackMate plugin of the FIJI
software. Only tracks lasting more than 20 minutes were considered.
Chemotaxis plots and Forward Migration Index (FMI-Y) were obtained with
the Chemotaxis and Migration tool from ibidi.
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FIG E1. Segregation ofWDR1 variants in core pedigrees. A, Pedigree of family A and Sanger sequencing of
WDR1 at position 145-147. DNA sequences correspond to the antisense strand. B, Pedigree of family B and
Sanger sequencing of WDR1 at position 572-574. DNA sequences correspond to the antisense strand. C,
Pedigree of family C and Sanger sequencing of WDR1 at positions 500-502 and 572-574. DNA sequences
correspond to the sense strand.
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FIG E2. T-cell parameters in patients carrying WDR1 variants. A, Representative Western blot analysis of
WDR1 expression in lysates from expanded T cells derived from 2 healthy donors, patients P1 to P5, and
parents of patients P2 to P4. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown as a loading
control. B, Flow cytometry–based quantification of the proportion of the stem memory T-cell subset in
PBMCs from healthy donors and patients. C, TCR downregulation assessed by using flow cytometry after
stimulation with the indicated concentrations of anti-CD3 antibody for 1 hour. D, Analysis of T-cell
proliferation after 72 hours of stimulation of PBMCs with soluble anti-CD3/CD28 antibody or bead-coated
anti-CD3/CD28 antibody. E, Proportion of expanded T cells that migrated in 4 hours across a transwell
membrane in response to the indicated concentrations of CXCL12. F, Residual number of P815 target cells
after 24 hours of incubation with purified CD81 T cells from a healthy donor and patients P1 to P4 at a 1:1
ratio. P815 cells had been coated previously with the indicated concentrations of anti-CD3 antibody to
stimulate CD81 T-cell lytic activity. HD, Healthy donor.
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FIG E3. Mitochondrial membrane potential and apoptosis in neutrophils from patients carrying WDR1
variants. A, Mitochondrial membrane potential monitored by using flow cytometric staining of JC-1 in
neutrophils from 2 healthy donors and patients P2 to P4 on isolation and after 4.5 hours in complete
RPMI medium. B, Apoptosis in neutrophils from 2 healthy donors and patients P1 to P4, as determined
by staining for Annexin V and propidium iodide, after 0, 7, or 16 hours of incubation in complete medium.
C, Quantification of apoptosis determined by staining for Annexin V and propidium iodide. HD, Healthy
donor.
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FIG E4. SHMpatterns in B cells from patients carryingWDR1 variants.A, Representative flow cytometric dot
plots of the analysis of B-cell subsets in PBMCs from 4 healthy donors and patients P3 to P6. Data stem from
2 distinct experiments (experiment 1: HD2, P3, and P4; experiment 2: HD3 to HD5 and P5 to P6). B, Relative
frequencies of transitions and transversions at GC and mutations at AT are shown as mean values for 4
healthy donors and patients P1 to P4. C, CDR3 length and proportions of antigen-selected sequences,
deletions, and N-nucleotide rearrangements are shown for 4 healthy donors and patients P1 to P4.
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FIG E5. Bonemarrow histology. A, Immunohistology staining for hematoxylin and eosin (H&E), CD71, CD79a,
or terminal deoxynucleotidyl transferase (TdT) in the bone marrow from patient P2. B, Immunohistology
staining for reticulin (Ret), Pax5, CD117, CD61, CD22, and CD3 in bone marrow from patients P1 and P2.
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FIG E6. Migration toward CCL19 in B-LCLs from patients carryingWDR1 variants.A, Tracks of B-LCLs from 2
healthy donors and patients P1 and P3 exposed to a gradient of CCL19. B, Directional migration of individual
cells assessed as the forward migration index along the axis coincident with orientation of the CCL19
gradient.
J ALLERGY CLIN IMMUNOL
nnn 2018
16.e8 PFAJFER ET AL
TABLE E1. Hematologic values pertaining to anemia
Family A B C
Patient 1 2 3 4 5 6
Date 8/2014 3/2017 9/2014 8/2016 8/2014 3/2017 8/2014 3/2017 2/2016 12/2017 1/2016 12/2016
Hemoglobin (g/dL) 8.7 11.5 8.0 7.9 5.83 13.7 9.61 13.8 9.6 11.8 9.6 9.7
MCV (fL) 71.6 78.5 49 47.9 50.9 78.3 65.6 84.2 71.1 72.5 66 66.2
RDW (%) 13.8 15 24.6 23.1 20 13.9 18.5 13 16 15.5 19.9 18.9
Reticulocyte (%) 0.8 0.95 2.4 2 NA NA NA NA NA NA 1.8 2
Direct coombs Negative Negative Negative Negative NA Negative NA NA NA NA Negative Negative
Ferritin (ng/mL) NA 37.5 11.8 13.1 6.23 66.11 22 83 NA NA 28.9 NA
Total iron (mg/dL) 16 51 6 8 12 47 13 24 NA NA 12 NA
Total iron-binding
capacity (mg/mL)
169 398 264 303 395 380 273 304 NA NA 295 NA
Transferrin saturation (%) NA NA 2 2 3 12.3 4.7 7.8 NA NA 4 NA
NA, Not available/applicable; RDW, red cell distribution width.
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TABLE E2. Febrile episodes and concomitant biological parameters in patients 1, 2, and 6
Family A B C
Patient 1 2 6
Date 2/2014 1/2017 9/2014 12/2016 1/2016 12/2016
Body temperature
during
representative
febrile episodes (8C)
38.5 38.8 38.0 39.0 38.5 38.2
Leukocyte count (cells/mL) 20,330 (4,500-10,500) 18,460 (4,500-10,500) 15,410 (4,500-10,500) 13,910 (4,500-10,500) 13,910 (4,500-10,500) 24,820 (4,500-10,500)
Lymphocyte count (cells/mL) 830 (1,500-7,000) 1,250 (1,500-7,000) 4,230 (1,500-7,000) 1,360 (1,500-7,000) 1,360 (1,500-7,000) 1,420 (1,500-7,000)
Neutrophil count (cells/mL) 18,020 (1,500-8,000) 15,810 (1,500-8,000) 9,860 (1,500-8,000) 11,670 (1,500-8,000) 11,670 (1,500-8,000) 22,470 (1,500-8,000)
Hemoglobin 9.7 (11-16) 13 (11-16) 8.6 (11-16) 7.6 (11-16) 9.6 (11-16) 11.3 (11-16)
Thrombocyte count
(cells/mL)
27,000 (15,000-400,000) 47,000 (15,000-400,000) 284,000 (15,000-400,000) 406,000 (15,000-400,000) 213,000 (15,000-400,000) 117,000 (15,000-400,000)
Ferritin (ng/mL) 236 (7-140) 347 (7-140) 11.8 (7-140) 20.1 (7-140) 28.9 (7-140) NA
Fibrinogen (mg/dL) 575 (200-400) NA NA 405 (200-400) 281 (200-400) NA
SAA (mg/L) 140 (0-6) >216 (0-6) NA 190 (0-6) 12.8 (0-6) 190 (0-6)
CRP (mg/dL) 12 (<0.5) 5.5 (<0.5) 8.23 (<0.5) 14.9 (<0.5) 10.24 (<0.5) 14.09 (<0.5)
Erythrocyte sedimentation
rate (mm/h)
55 100 39 28 67 91
Specific clinical features
accompanying
febrile episodes
Aphthous stomatitis,
diarrhea
Aphthous stomatitis,
diarrhea,
vomiting
Pneumonia, otitis media,
common skin abscess
Pneumonia, otitis media,
typhlitis, aphthous stomatitis
Bullous skin lesions,
pneumonia
Bullous skin lesions,
aphthous stomatitis,
pneumonia
Values in parentheses indicate normal ranges. Patients 3, 4, and 5 did not present with febrile episodes during the current clinic follow-up. Data pertaining to the occurrence of previous episodes are not available.
CRP, C-reactive protein; NA, not available/applicable; SAA, serum amyloid A.
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TABLE E3. Homozygous genetic variants segregating within families 1 and 2 together with WDR1 mutations
Gene Chromosome Genomic position SNP ID R A AA CADD Biological function/phenotypic effect Variant in previous reports
Family A
WDR1 4 10099458 G C H145Q 13.3 — —
WFS1 4 6302816 rs35031397 C G L432V 23.7 Wolfram syndrome-1 is a rare and severe autosomal
recessive neurodegenerative disease characterized by
diabetes mellitus, optic atrophy, diabetes insipidus,
and deafness (DIDMOAD). Additional clinical
features can include renal abnormalities, ataxia,
dementia or mental retardation, and diverse
psychiatric illnesses.
Variant found in heterozygosity in patients with diabetes
and deafness (WFS1 mutations in Spanish patients
with diabetes mellitus and deafness)*
MTMR1 X 149895690 rs376319087 A G K119R 22.1 MTMR1 might play a role in muscle formation and
might represent another target for abnormal mRNA
splicing in myotonic dystrophy.
—
CLDN25 11 113650613 G T Q32H 10,15 This gene encodes a member of the claudin family.
Claudins are integral membrane proteins and
components of tight junction strands. Tight junction
strands serve as a physical barrier to prevent solutes
and water from passing freely through the
paracellular space between epithelial or endothelial
cell sheets and also play critical roles in maintaining
cell polarity and signal transductions.
—
BLID 11 121986544 T C I29M 0.008 BLID functions as a proapoptotic molecule through the
caspase-dependent mitochondrial pathway of cell
death.
—
OTOP1 4 4199758 rs145349079 T C Y268C 23.8 This gene encodes a transmembrane protein that
belongs to the otopetrin domain protein family and is
required for formation of otoconia and otoliths,
calcium carbonate biominerals within the inner ear of
mammals that are required for detection of linear
acceleration and gravity.
—
CPSF1 8 145624679 G C T460S 8.967 Cleavage and polyadenylation specificity factor (CPSF)
is a multisubunit complex that plays a central role in
3-prime processing of pre-mRNAs.
-
Family B
WDR1 4 10077108 T A D572V 28 — —
TM4SF19 3 196054442 rs188688105 G A T7M 2.304 The protein encoded by this gene is a member of the 4-
transmembrane L6 superfamily. Members of this
family function in various cellular processes,
including cell proliferation, motility, and adhesion
through their interactions with integrins. In human
brain tissue this gene is expressed at high levels in the
parietal lobe, occipital lobe, hippocampus, pons,
white matter, corpus callosum, and cerebellum.
—
A, Alternative base; AA, amino acid substitution; R, reference base; SNP ID, reference single nucleotide polymorphism number.
*Domenech et al, Eur J Hum Genet 2002;10:421-6.
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